Brief: Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences To Advance Phase 3 Development And Commercialization Of Zumilokibart
BRIEF-Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences To Advance Phase 3 Development And Commercialization Of Zumilokibart May 27 (Reuters) - Apogee Therapeutics Inc APGE.O:
APOGEE THERAPEUTICS ANNOUNCES $1.3 BILLION STRATEGIC FINANCING COLLABORATION WITH BLACKSTONE LIFE SCIENCES TO ADVANCE PHASE 3 DEVELOPMENT AND COMMERCIALIZATION OF ZUMILOKIBART
APOGEE THERAPEUTICS INC - DEAL INCLUDES UP TO $800 MILLION SYNTHETIC ROYALTY AND UP TO $500 MILLION SENIOR DEBT
APOGEE THERAPEUTICS INC - BLACKSTONE TO PROVIDE UP TO $800 MILLION SYNTHETIC ROYALTY FUNDING FOR 15 YEARS
APOGEE THERAPEUTICS INC - REMOVES CASH RUNWAY END DATE GUIDANCE AFTER BLACKSTONE AGREEMENT
APOGEE THERAPEUTICS INC - UP TO $400 MILLION ADDITIONAL FUNDING AVAILABLE UPON FDA APPROVAL OF ZUMILOKIBART
APOGEE THERAPEUTICS INC - FIRST $400 MILLION PREAPPROVAL FUNDING IN 3 TRANCHES BASED ON DEVELOPMENT MILESTONES
Source text: ID:nGNX9TcsB6
Further company coverage: APGE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)